No Data
Breast Cancer Treatment From Daiichi Sankyo, AstraZeneca Approved in U.S.
Japanese stock buybacks this week (5/11~5/15)
――――5/11――――$ORIX(8591.JP)$ will buy back up to 100 million shares, 9.1% of its outstanding shares (excluding its own shares), for an amount of JPY¥ 250 billion.$Daiichi Sankyo(4568.JP)$ will cancel 3
Daiichi Sankyo Corrects FY2025 Presentation Materials Without Changing Financial Results
Daiichi Sankyo: (Correction) Regarding a Partial Correction to the "Supplementary Financial Statements for Fiscal Year 2025"
Stock Materials for Today: Daiichi Sankyo's operating profit for the fiscal year ending March 2026 is expected to decrease by 31%.
◆Daiichi Sankyo (4568) reported a 31% decrease in operating profit to JPY 229 billion for the fiscal year ending March 2026, due to loss compensation expenses incurred from contract manufacturing partners. [/20260511NNN0188][/20260511NNN0188] ◆Estee (4951) has revised downward its operating profit target in the mid-term management plan, considering factors such as rising raw material costs. ◆Yamaha (7951) forecasts increased revenue and profit for the fiscal year ending March 2027. [/20260511NNN0151] ◆AEON (8267) projects operating profit of JPY 500 billion for the fiscal year ending March 2030.
Daiichi Sankyo To Go Ex-Dividend On March 30th, 2027 With 50 JPY Dividend Per Share
May 12th (Japan Standard Time) - $Daiichi Sankyo(4568.JP)$ is trading ex-dividend on March 30th, 2027.Shareholders of record on March 31st, 2027 will receive 50 JPY dividend per share. The ex-